BAUSCH HEALTH
LIVE

Serial Number

87884008

Owner

Bausch & Lomb Incorporated

Attorney

Robert J. Gorman

First Use Date

Mar 12, 2014

Filing Date

Apr 19, 2018

Add to watchlist:

No watchlists yet
View on USPTO

BAUSCH HEALTH Trademark

Serial Number: 87884008 • Registration: 6974682

BAUSCH HEALTH is a trademark filed by Bausch & Lomb Incorporated on April 19, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Bausch & Lomb Incorporated (17 trademarks)

1400 N. Goodman Street
Rochester, NY 14609

Entity Type: 03

Trademark Details

Filing Date

April 19, 2018

Registration Date

February 7, 2023

First Use Anywhere

March 12, 2014

First Use in Commerce

March 12, 2014

Published for Opposition

November 5, 2019

Goods & Services

Providing on-line publications in the nature of newsletters, pamphlets and bulletins in the field of health issues; newsletters, articles, informational brochures and web-based tools

Providing a website featuring information and advice in the field of health issues

cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, hepatologicalrespiratory, neurological, respiratory, neurological, hormonal, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema and vitamin preparations, all in the form of tablets or powder or soft gelatin capsules or hard gelatin capsules; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; Pharmaceutical preparations, namely, retinoids, for the treatment of skin related diseases, cancer and precancerous conditions, and disorders related to the modulation of apoptosis; vitamin supplement distributed by prescription only; pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;, namely, diazepam rectal gel; Methyltestosterone for use in the treatment of hormone deficiencies; medicated skin lotion for the relief of itch caused by insect bites, eczema, sunburn and poison ivy; Preparations and substances for the relief of anorectal discomfort, inflammation, and irritation; hemorrhoidal suppositories; Pharmaceutical preparations for the treatment of irritable bowel syndrome; Drugs to treat opioid-induced constipation; Psychotropic preparations; Cough medicine in the nature of saline solution, namely, a spray for nasal dryness due to allergies, cold and flu; Dermotherapeutic preparation for use in the treatment of obesity; pharmaceutical preparations for the treatment of neurological disorders and movement disorders; antiobesity agent in the nature of a pharmaceutical preparation; and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; tranquilizers and sedatives; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 14, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 14, 2026 REAP
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Sep 10, 2025 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 25, 2025 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 6, 2023 ASCK
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 7, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 7, 2023 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jan 6, 2023 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jan 5, 2023 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jan 3, 2023 SUPC
USE AMENDMENT FILED
Jan 1, 2023 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 1, 2023 EISU
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 28, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 21, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 14, 2022 ASCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 10, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 10, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 10, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 10, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 10, 2022 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 12, 2022 EXRA
SOU EXTENSION 5 GRANTED
Jul 11, 2022 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 11, 2022 AITU
SOU EXTENSION 5 FILED
Jun 28, 2022 EXT5
SOU TEAS EXTENSION RECEIVED
Jun 28, 2022 EEXT
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jun 23, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Mar 9, 2022 ASCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 9, 2021 EXRA
SOU EXTENSION 4 GRANTED
Nov 7, 2021 EX4G
SOU EXTENSION 4 FILED
Nov 7, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 7, 2021 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 16, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 16, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 16, 2021 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 1, 2021 EXRA
SOU EXTENSION 3 GRANTED
May 30, 2021 EX3G
SOU EXTENSION 3 FILED
May 30, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
May 30, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 3, 2020 EXRA
SOU EXTENSION 2 GRANTED
Dec 1, 2020 EX2G
SOU EXTENSION 2 FILED
Dec 1, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 1, 2020 EEXT
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Nov 25, 2020 ASCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 19, 2020 EXRA
SOU EXTENSION 1 GRANTED
May 15, 2020 EX1G
SOU EXTENSION 1 FILED
May 15, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
May 15, 2020 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 11, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 11, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 11, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 11, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 11, 2020 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 31, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 5, 2019 NPUB
PUBLISHED FOR OPPOSITION
Nov 5, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 16, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 28, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 28, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 28, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 28, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 28, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 7, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 6, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2019 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2019 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 15, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 14, 2019 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 14, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 14, 2019 REAP
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 15, 2018 GNRN
NON-FINAL ACTION E-MAILED
Aug 15, 2018 GNRT
NON-FINAL ACTION WRITTEN
Aug 15, 2018 CNRT
ASSIGNED TO EXAMINER
Aug 9, 2018 DOCK
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2018 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2018 NWOS
NEW APPLICATION ENTERED
Apr 23, 2018 NWAP